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Abstract
Background: The diagnostic entity malignant fibrous histiocytoma (MFH) of bone is, like its soft tissue counterpart,
likely to be a misnomer, encompassing a variety of poorly differentiated sarcomas. When reviewing a series of 57
so-called MFH of bone within the framework of the EuroBoNeT consortium according to up-to-date criteria and
ancillary immunohistochemistry, a fourth of all tumors were reclassified and subtyped.
Methods: In the present study, the cytogenetic data on 11 of these tumors (three myoepithelioma-like sarcomas,
two leiomyosarcomas, one undifferentiated pleomorphic sarcoma with incomplete myogenic differentiation, two
undifferentiated pleomorphic sarcomas, one osteosarcoma, one spindle cell sarcoma, and one unclassifiable
biphasic sarcoma) are presented.
Results: All tumors were high-grade lesions and showed very complex karyotypes. Neither the overall pattern
(ploidy level, degree of complexity) nor specific cytogenetic features distinguished any of the subtypes. The
subgroup of myoepithelioma-like sarcomas was further investigated with regard to the status of the EWSR1 and
FUS loci; however, no rearrangement was found. Nor was any particular aberration that could differentiate any of
the subtypes from osteosarcomas detected.
Conclusions: chromosome banding analysis is unlikely to reveal potential genotype-phenotype correlations
between morphologic subtypes among so-called MFH of bone.
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Background
Only some decades ago, malignant fibrous histiocytoma
(MFH) was considered the most common soft tissue sar-
coma among adults. However, with the introduction of
more stringent morphologic and immunohistochemical
criteria, it turned out that it was possible to reclassify the
vast majority of those tumors as, e.g., poorly differen-
tiated leiomyosarcomas or dedifferentiated liposarcomas
[1]. For the few cases in which no signs of differentiation
could be discerned, the term undifferentiated pleo-
morphic sarcoma (UPS) was introduced [2,3].
Importantly, the subclassification of MFH tumors into
different lineages of differentiation was shown to be of
prognostic significance, with immunohistochemical
expression of smooth muscle actin (incomplete myogenic
differentiation) being associated with worse outcome [4].
In the latest edition of the WHO classification of soft
tissue and bone tumors [2], the new view on MFH
tumors was introduced for the soft tissue lesions [3],
but not for bone tumors [5]. According to the WHO
description, MFH of bone is a highly aggressive primary
bone tumor of unknown cellular origin. The tumor has
a rather typical and distinct clinical presentation as a
lytic destructive lesion, affecting adults and showing a
predilection for the long bones of the lower extremities.
Histologically, it is characterized by a mixture of
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any medium, provided the original work is properly cited.spindle-shaped, histiocytoid and pleomorphic cells. Aty-
pical nuclei and mitoses are common, and multinu-
cleated tumor and osteoclastic giant cells and
inflammatory cells are often present. There are no speci-
fic immunohistochemical markers, and it may thus be
difficult to distinguish it from other bone tumors with
scarce or no osteoid formation, such as fibrosarcoma
and poorly differentiated osteosarcoma [5].
In an attempt to evaluate whether a reclassification of
MFH of bone, similar to that for soft tissue tumors, is
possible, 57 tumors classified as MFH of bone were
reviewed by a panel of expert bone pathologists from
the EuroBoNeT network, a network of excellence study-
ing the pathology and genetics of bone tumors [Romeo
et al: Malignant fibrous histiocytoma and fibrosarcoma
of bone in 2011: What’s new? Submitted]. Of these, 11
had been subjected to chromosome banding analysis
after short-term culturing. In the present study, we
report the cytogenetic findings, and compare the karyo-
typic features with those of the most important differen-
tial diagnoses.
Methods
Patients
Clinical data are summarized in Table 1. Case numbers
correspond to those in the article by Romeo et al.
[Malignant fibrous histiocytoma and fibrosarcoma of
bone in 2011: What’sn e w ?S u b m i t t e d ] ,i nw h i c ht h e
morphologic and immunohistochemical features of a
larger series of so-called MFH of bone are detailed. In
brief, the present study included six men and five
women, aged 29-76 years at diagnosis. All tumors were
primary lesions; from Case 91 also a lung metastasis
could be analyzed. Tumor locations were lower (n = 6)
and upper (2) extremities, pelvis (2), and unknown (1).
Histopathologic examination
T h e1 1t u m o r sw e r eo r i g i n a l l yd i a g n o s e da sM F Ho f
bone, but were all reclassified and subtyped as described
elsewhere [Romeo et al: Malignant fibrous histiocytoma
and fibrosarcoma of bone in 2011: What’sn e w ?S u b -
mitted] by a board of pathologists (S.R., J.V.M.G.B., R.T.,
N.A., P.C.W.H., A.P.D.T.). Three tumors were classified
as myoepithelioma-like sarcoma, two as leiomyosar-
coma, one as UPS with incomplete myogenic differentia-
tion, two as UPS, one as osteosarcoma, one as spindle
cell sarcoma not otherwise specified, and one as an
unclassifiable biphasic sarcoma (Table 1). All tumors
were classified as high-grade (grade 3) lesions.
Chromosome banding analysis
Fresh tumor samples were processed for G-banding ana-
lysis as described [6], and karyotypes were described
according to the guidelines in ISCN 2009 [7].
Fluorescence in situ hybridization (FISH)
FISH using break-apart probes for the EWSR1 and FUS
genes was performed on interphase nuclei in cut sec-
tions from paraffin-embedded tumors reclassified as
myoepithelioma-like sarcomas. For details, see Romeo et
al. [Malignant fibrous histiocytoma and fibrosarcoma of
bone in 2011: What’s new? Submitted].
Results
The karyotypes, which were based on G-banding alone,
were highly complex in all cases (Table 1). The only
exception was the primary lesion of Case 91, showing
addition of unknown material to the long arm of chromo-
some 19 and a supernumerary marker chromosome as the
sole changes; however, the lung metastasis of the same
tumor showed an unrelated highly complex karyotype.
The chromosome number varied from 32 to approxi-
mately 190, with a near-diploid or near-triploid modal
chromosome number in five and three cases, respectively.
In all cases there were aberrations that could not be
resolved, resulting in karyotypes with chromosomes with
material added from an unknown chromosome and/or
multiple marker chromosomes. In spite of the large num-
ber of structural rearrangements, only a few breakpoints
were recurrent: 1p11, the centromeric region of chromo-
some 5 and 12q22 were each affected in three cases, and
involvement of 1p13, the centromeric region of chromo-
some 1, 7q11, 9p21, 14p11, 16p13, 19p13, 19q13, 21p11,
21q22 and 22q13 was seen in two cases each. A total of 68
different chromosome bands were involved in structural
rearrangements; two-thirdso ft h e s ew e r en e a r - c e n t r o -
meric (p11-q11; 26 bands) or terminal (19 bands) chromo-
some bands. The only breakpoints which were recurrent
in, and restricted to, a particular morphologic subtype
were 14p11 in UPS and 16p13 in myoepithelioma-like sar-
comas. Bearing in mind the incompleteness of the karyoty-
pic descriptions, no attempts were made to identify
chromosomal imbalances resulting from numerical or
unbalanced structural rearrangements. Only one balanced
translocation, a t(8;9)(q22;p24) in a myoepithelioma-like
sarcoma, was found. Neither this aberration, nor any of
the other unbalanced translocations or deletions corre-
sponded to any known tumor-specific rearrangement.
Cytogenetic signs of gene amplification, in the form of
double minutes, homogeneously staining regions or ring
chromosomes, were seen in two cases.
Interphase FISH analysis for rearrangement of the
EWSR1 and FUS loci was successfully performed in two
of the three cases of myoepithelioma-like sarcoma.
Neither case showed a rearrangement.
Discussion
The genetic information on so-called MFH of bone is
limited. In a series of 19 cases, TP53 mutations were
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Page 2 of 5Table 1 Karyotypes of cytogenetically abnormal tumors previously diagnosed as MFH of bone
Case No.
1 Age/Sex Diagnosis
2 Site Karyotype
3 FISH
4
Case 63 + 64 61/M Myoepithelioma-like sarcoma Humerus 42, XY, der(1)t(1;10)(p11;q11),
+dic(1;15)(p13;q26), add(6)(p11),-7,
add(7)(p22), t(8;9)(q22;p24),-10,
add(10)(q11), add(12)(q24),-15,
+add(16)(p13),-17, add(19)(p13),-20,
-20, r(21)(p13q22), r(22)(p13q13),
+1-2mar
EWSR1-,
FUS-
Case 69 49/M Myoepithelioma-like sarcoma Tibia 77-94 < 4n >, X,-X, del(X)(q21),-Y, add(1)
(q25), del(2)(p14)x2,-3,-4, der(4)t(4;5)
(q?31;q?15),-5,-5,-6,-8,-8,-9,-9,-9,-9,
-10,-10, add(11)(q13)x2, add(12)
(q22)x2,-13,-15,-16, add(16)(p13),-17,
-17,-17,-17,+18,-19, add(20)(p13)x4,
-21,-21, inc
EWSR1-,
FUS-
Case 88 70/F Myoepithelioma-like sarcoma Femur 54-58 < 2n >, XX,+der(1;9)(q10;q10),
+i(5)(p10),+add(6)(q13),+7,+del(8)
(q21-22)x2,-9,+15,+20,+20,+20,+22,
+22,+3-4 mar
Failure
Case 89 53/M Leiomyosarcoma Femur
(bone infarct)
58-61, XX,-Y,+i(1)(q10),-3,-4,-5,-6,
+add(7)(q11), add(9)(p21)x2,-10,-10,
-11, i(11)(p10),-12, add(12)(p13)x2,
-13,-14, i(15)(q10),-16,-17,-17, add(19)
(q13),+20,+i(20)(p10),-21, der(21)
t(1;21)(p13;p11),-22,+2-4mar
ND
Case 98
5 47/M Leiomyosarcoma Os ileum 130-190 < 6n-8n >, X?inc ND
Case 68 76/F UPS with incomplete myogenic differentiation Femur 59-113, X?, inc/46, XX, inv(9)(p11q12)c ND
Case 66 68/F UPS Tibia 84-106 < 5n >, XX,-X,-X,-X,?add(1)
(q42), del(1)(p11), del(1)(q12), der(1)
add(1)(q42)del(1)(p11), der(1)add(1)
(q44)add(1)(p11)hsr(?), add(2)(q3?3),
i(3)(p10),-4, der(4)add(4)(p16)hsr(4)
(p16), i(5)(q10),+add(6)(q11)x2,-7,
der(8)t(1;8)(p22;p2?3)x1-2, i(10)(q10),
-13,-13, add(13)(p11),-14, add(14)(p11),
?i(14)(q10),-15,-15,-16,-16,-17,-17,
?add(17)(p11),-18,-18, der(18)add(18)
(p11)hsr(?),-19,-21,-21,-22,?add(22)
(q13), inc
ND
Case 105 66/F UPS Unknown 67-77, XX,-X,+1,-2, add(2)(p11)x2,-3,
+4,-8,-8,+9, dic(9;17)(p21;p13)x2,+10,
+12,+13, der(14)t(2;14)(q11;p11),+16,
+17,+19,-20,-22
ND
Case 100 52/F Osteosarcoma Os ischium 32-44, X,-X, add(1)(p11),-3,-4,-6,-9,-10,
der(12)add(12)(p12)del(12)(q22),-13,
-13,-14,-15,-16,-17,-18,-19,-21, add(21)
(p11),-22, der(22)t(3;22)(p11;q11)
ND
Case 86 + 94 51/M SCS NOS
(metastatic carcinoma?)
Femur 44-48, XY, der(1)t(1;18)(p36;q11),
del(4)(p15), del(7)(q22), del(8)(p11),
dic(8;10)(p11;p?),-13,-15, del(16)(q22),
add(19)(p13), add(20)(q13),+add(21)
(q22),+r,+1-7mar/80-83, idemx2
ND
Case 91 29/M Dubious biphasic sarcoma Humerus
Lung met.
47, XY, add(19)(q13),+mar
88-90, XXYY, der(2)t(2;7)(p21;q11)x2,
-4,-4,+i(5)(p10)x2,-7,-7,-12, del(12)
(q22)x2, add(13)(q22)x2,+18,-21,-21,
+3-4 mar
ND
1Case numbers are identical to those in the publication by Romeo et al. [6].
2All tumors were classified as grade 3 tumors (3-grade scale). UPS = undifferentiated pleomorphic sarcoma; SCS NOS = spindle cell sarcoma not otherwise
specified.
3All karyotypes are composite karyotypes.
4ND = not done.
5Karyotype on sample obtained after chemotherapy.
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affected [8]. Another 26 cases were analyzed by chromo-
some-based comparative genomic hybridization (CGH),
revealing copy number changes in 23 of them [9]. The
results indicated a different pattern of chromosomal
imbalances compared to that in high-grade osteosarco-
mas, fibrosarcomas of bone, and soft tissue MFHs.
Gains were more common than losses, with approxi-
mately one-third of the cases displaying gain of material
from chromosome arms 1q, 7p, 7q, 8q, 9q, or 15q [9].
Whereas CGH analyses are more reliable in providing
information on copy number changes, chromosome
banding analyses have the advantage of identifying
balanced chromosomal exchanges, as well as revealing
the ploidy level and the extent of intercellular variation.
However, only five cases with abnormal karyotypes have
previously been reported, all presenting complex karyo-
types without any obvious unifying feature [6,10-13].
The results of the present study add to the conclusion
that tumors previously recognized as MFH of bone are
genetically highly complex, and that there are few recur-
rent aberrations that can be detected by chromosome
banding analysis. Neither the overall pattern of chromo-
some aberrations (aneuploidy, high level of complexity
or intercellular variation) nor specific findings (e.g., par-
ticular breakpoints or aberrations) distinguish these
tumors cytogenetically from their main differential diag-
nostic entity - osteosarcoma.
The present study included too few cases of each sub-
type to allow any meaningful comparison between the
new morphologic subgroups; until more cases have been
analyzed, the finding of two recurrent breakpoints in
UPS (14p11) and myoepithelioma-like sarcoma (16p13)
should be considered chance findings. One of the mor-
phologic subgroups identified at the histopathologic re-
evaluation - myoepithelioma-like sarcoma - could poten-
tially harbor a distinctive genetic aberration. Antonescu
and co-workers recently showed that gene fusions invol-
ving the EWSR1 gene are common in myoepithelial
tumors of soft tissue and bone [14]. An EWSR1/
POU5F1, EWSR1/PBX1 or EWSR1/ZNF444 fusion gene,
or a rearrangement of the EWSR1 gene with unknown
fusion partner, was detected in close to half of the soft
tissue lesions, and in four out of five bone tumors. How-
ever, all EWSR1-positive bone tumors were classified as
benign; the single malignant myoepithelial tumor of
bone was negative. However, one of the seven sarcomas
analyzed in the study by Romeo et al. [Malignant fibrous
histiocytoma and fibrosarcoma of bone in 2011: What’s
new? Submitted] - reclassified as myoepthelioma-like
sarcoma - had an EWSR1/NFATC2 fusion, adding to the
growing morphological spectrum of this recently
described gene fusion [15]. In the present study, only
two of the cases diagnosed as myoepithelial-like
sarcomas could be analyzed by FISH for EWSR1-rear-
rangement, and both were negative. Combined, these
data indicate that EWSR1-rearrangements are rare in
malignant bone tumors showing myoepithelial
differentiation.
Based on the present, admittedly small, study it seems
safe to conclude that traditional chromosome banding
analysis cannot be used to distinguish between the
many different morphologic subtypes that may be dis-
cerned among so-called MFH of bone. Nor is there any
indication that the karyotypic features of any of the sub-
groups differ from those in osteosarcoma. Quite possi-
bly, also high resolution, array-based genomic analyses
will fail to detect any distinct features, as previously
shown for soft tissue tumors [16], but that needs to be
properly evaluated in larger series.
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